Morgan Stanley Capital International (MSCI), the leading global index provider, recently announced its latest quarterly review results, with Alphamab Oncology (9966.HK) being included in the MSCI Global Small Cap Index. The changes will take effect after the market close on May 30, 2025 (Friday).
The MSCI Global Small Cap Index, a key component of MSCI's flagship index system, tracks the performance of small- and medium-cap listed companies worldwide. Covering 23 developed markets and 24 emerging markets, the index selects constituents based on core criteria including market capitalization, liquidity, industry distribution, and corporate governance. Alphamab's inclusion in this index signifies that its growth potential, market value, and trading liquidity in the biopharmaceutical sector have met global mainstream standards. This will further enhance its influence in the global capital markets.
As an innovative biopharmaceutical company, Alphamab focuses on the research and development of cutting-edge technologies in the field of oncology and has established differentiated competitive advantages. By leveraging its proprietary core technology platforms including glycan-specific conjugation, linker-payload, dual-payload conjugation, and bispecific antibodies, the Company has developed a product portfolio with global competitiveness. Alphamab has achieved a number of significant research milestones, demonstrating its strong technological foundation and sustained innovation capabilities. Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor, was approved for marketing, providing a safer and more convenient tumor immunotherapy for patients. HER2 bispecific antibody KN026 and HER2 biparatopic ADC JSKN003 are both undergoing several phase III clinical trials and are expected to offer effective and safe treatment options for cancer patients. Multiple clinical trials of bispecific ADC JSKN016 and JSKN033 are currently undergoing smoothly, with preliminary data demonstrating promising efficacy and favorable safety profile. In 2024, the Company entered into strategic partnerships with well-known domestic and international pharmaceutical companies including Glenmark, ArriVent, and CSPC. These collaborations have not only expanded the Company's global R&D and commercialization efforts, but also led to profitability for the first time on an annual basis since inception.
Moving forward, Alphamab Oncology will continue to optimize and upgrade its therapeutic pipeline, engage in global competition through diversified strategic collaborations, and accelerate the R&D and commercialization of innovative new drugs, aiming to deliver more and better treatment options to cancer patients worldwide.
About Alphamab Oncology
Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.
The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
